GlassScriptPhysician profile
Michael Paul Davis
NPI 1780666578
$3,722.57
in general payments reported to CMS, 2019-2025
38 companies · $337 in 2025
The $337 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,125 · 2020: $259 · 2021: $429 · 2022: $606 · 2023: $651 · 2024: $316 · 2025: $337.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,239 · Education: $64.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,239.35 |
| Education | $64.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $583.77 | 2019-2025 | Atacand, Farxiga, Brilinta |
| Novartis Pharmaceuticals Corporation | $445.67 | 2019-2025 | |
| Pfizer INC. | $334.15 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $332.38 | 2019-2023 | Xarelto |
| Merck Sharp & Dohme LLC | $184.17 | 2021-2025 | Verquvo, Zerbaxa |
| Amarin Pharma, INC. | $172.53 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $159.14 | 2022-2024 | Camzyos, Eliquis |
| Amgen INC. | $131.43 | 2019-2023 | Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $131.38 | 2019-2023 | Jardiance |
| Cardiovascular Systems INC. | $104.10 | 2021 | |
| Abiomed | $98.94 | 2019-2025 | |
| Penumbra, INC. | $92.45 | 2023 | Indigo System |
| Abbott Laboratories | $89.99 | 2020-2022 | |
| Boston Scientific Corporation | $87.90 | 2019-2025 | Watchman Access System |
| Bayer Healthcare Pharmaceuticals INC. | $83.71 | 2021-2025 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vifor Pharma, INC. | $80.84 | 2023 | Veltassa, Korsuva |
| Actelion Pharmaceuticals US, INC. | $77.24 | 2020-2023 | Uptravi, Opsumit |
| Scpharmaceuticals INC. | $77.15 | 2024 | |
| Sanofi-Aventis U.S. LLC | $61.12 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $51.69 | 2024-2025 | Lifevest |
| Medtronic Vascular, INC. | $39.46 | 2019-2020 | |
| Astellas Pharma US INC | $33.23 | 2025 | Cresemba |
| Medtronic, INC. | $32.16 | 2021-2024 | Venaseal |
| Cvrx, INC. | $24.77 | 2023-2024 | Barostim Neo System |
| Avinger INC. | $24.73 | 2021 | |
| Impulse Dynamics (USA) INC. | $23.72 | 2023 | Optimizer |
| Cordis US Corp. | $20.56 | 2021 | |
| Novo Nordisk INC | $18.71 | 2024 | Ozempic |
| Hologic Sales and Service, LLC | $18.28 | 2022 | |
| Genzyme Corporation | $16.62 | 2019 | |
| Argon Medical Devices, INC. | $15.04 | 2022 | |
| Viiv Healthcare Company | $14.99 | 2025 | Apretude |
| Irhythm Technologies, INC. | $14.63 | 2023 | Zio Xt Patch |
| Vivaquant INC, Dba Rhythm Express | $13.75 | 2025 | Rhythm Express |
| Philips North America LLC | $11.80 | 2021 | |
| Z-Medica, LLC | $11.14 | 2019 | |
| Zoll Circulation INC | $9.23 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Davis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.